Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| EAY191-A3 | Alliance | A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers | Adult CIRB - Early Phase Emphasis | Available to Open | |
| EAY191-A6 | ECOG-ACRIN | A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations | Adult CIRB - Early Phase Emphasis | Available to Open | |
| EAY191-E4 | ECOG-ACRIN | A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors | Adult CIRB - Early Phase Emphasis | Available to Open | |
| EAY191-E5 | ECOG-ACRIN | A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tumors | Adult CIRB - Early Phase Emphasis | Available to Open | |
| EAY191-N2 | ECOG-ACRIN | A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1 | Adult CIRB - Early Phase Emphasis | Available to Open | |
| EAY191-N4 | ECOG-ACRIN | Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial | Adult CIRB - Early Phase Emphasis | Available to Open | |
| EAY191-N5 | ECOG-ACRIN | A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial | Adult CIRB - Early Phase Emphasis | Available to Open | |
| EAY191-S3 | ECOG | EAY191-S3, Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors (A COMBOMATCH Treatment Trial) | Adult CIRB - Early Phase Emphasis | Available to Open | |
| EAZ171 | ECOG-ACRIN | Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women | Cancer Prevention and Control CIRB | Available to Open | |
| GOG-0198 | GOG | A Randomized Study of Tamoxifen Versus Thalidomide (NSC # 66847) in Patients with Biochemical-Recurrence-Only Epithelial Ovarian Cancer; Cancer of the Fallopian Tube; and Primary Peritoneal Carcinoma after First Line Chemotherapy | Adult CIRB - Late Phase Emphasis | Completed |